Latest News and Press Releases

Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant Additional cost optimization measures expected to realize total annual savings of...

•    Stefan Ries joins as CSO, bringing more than two decades of drug development experience in the pharmaceutical industry complemented by a background in venture capital •    Elena Ardini joins as...

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

NEW HAVEN, Conn., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...

– Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant – –...

Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates

– Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer – – Presented ARV-102 SAD and MAD data from the Phase 1 clinical trial in...

NEW HAVEN, Conn., July 30, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...

– ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (also known as AITL) and transformed follicular lymphoma – – In...

Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inf